XML 79 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2017
Accounting Policies [Abstract]  
Schedule of Significant Balance of Accounts Receivable

The Company has not experienced any loss on its deposits of cash and cash equivalents. Included in current assets are significant balances of accounts receivable as follows:

 

 

 

December 31,

 

 

 

2017

 

 

2016

 

Astellas Pharma Inc. (“Astellas”)—Related party

 

 

47

%

 

 

39

%

AstraZeneca AB (“AstraZeneca”)

 

 

53

%

 

 

61

%